Lonza plans new ADC manufacturing site and workforce boost to capture commercial market
Lonza said it aims to become a leading supplier of antibody-drug conjugates (ADCs) for commercial use. The Swiss contract manufacturing organization highlighted the growing demand for ADCs and its strategy to capture that market.
The company announced that a new manufacturing site in Stein, Switzerland will be brought online next year. The facility will focus on large-scale ADC production and is expected to increase Lonza’s capacity.
In addition to the new plant, Lonza plans to expand its workforce to support the anticipated growth. The expansion reflects the firm’s confidence in the ADC segment’s future.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Lonza looks to ride ADC wave with upcoming factory, workforce expansion”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that